OR WAIT 15 SECS
Health Decisions announces that Moscow-based CRO Congenix has become a certified member of the Agile Clinical Network-a community of research partners with the goal of higher efficiency standards in complex global studies.
Congenix has received certification after completing "rigorous" training in Agile Clinical development techniques.
“Conducting global, multi-center trials with a network of regionally focused CROs offers many advantages over a single large CRO with international offices,” said Vladimir V. Novakovskiy, M.D., Ph.D., managing director, Clinical Operations and Regulatory Affairs, Congenix, LLP. “We look forward to bringing our extensive knowledge of Eastern Europe and Russia to the Agile Clinical Network to better assist sponsors with assessing investigators, cooperating with the local regulatory bodies, and recruiting study subjects.”
According to Dr. Novakovskiy, Eastern Europe and Russia offer sponsors high recruitment rates, an excellent selection of high-quality investigational sites, and lower cost per patient compared to Western Europe and the U.S. Other benefits include Russia’s highly centralized healthcare system and a large percentage of treatment-naïve patients.
A UK-registered CRO with offices in Moscow and Hercules, CA, USA, Congenix offers Phase I to IV services including regulatory affairs, clinical monitoring, project management, investigational site management, study supplies custom clearance, warehousing and distribution. Working within the Agile network, Congenix will have access to Health Decisions’ and other members’ high-efficiency data management systems, biostatistics expertise, medical writers, advanced data collection tools, and real-time reporting capabilities, as well as regional infrastructure around the world.
"We welcome Congenix to the Agile Clinical Network and look forward to our working together on global trials that will maximize efficiency and transparency,” said Rick Farris, Chief Operations Officer at Health Decisions. “Congenix will be a great asset to our Network as we expand its mission to deliver accurate trial results...”